{
    "clinical_study": {
        "@rank": "168201", 
        "acronym": "VCU-ART3", 
        "arm_group": [
            {
                "arm_group_label": "Anakinra (standard dose)", 
                "arm_group_type": "Experimental", 
                "description": "Anakinra 100 mg daily for 14 days"
            }, 
            {
                "arm_group_label": "Anakinra (high dose)", 
                "arm_group_type": "Experimental", 
                "description": "Anakinra 100 mg twice daily for 14 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra\n      standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)\n      measuring the effects on the acute rise and fall of the plasma C reactive protein levels\n      during the first 14 days."
        }, 
        "brief_title": "IL-1 Blockade in Acute Myocardial Infarction (VCU-ART3)", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n        In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria\n        and NONE of the Exclusion criteria.\n\n          1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and\n             ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous\n             leads that is new or presumably new\n\n          2. Planned or completed coronary angiogram for potential intervention\n\n          3. Age>21\n\n        EXCLUSION CRITERIA:\n\n          -  Inability to give informed consent\n\n          -  Pregnancy\n\n          -  Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association\n             III-IV)\n\n          -  Preexisting severe left ventricular dysfunction (EF<20%)\n\n          -  Preexisting severe valvular heart disease\n\n          -  Active infections (acute or chronic)\n\n          -  Recent (<14 days) or active use of anti-inflammatory drugs (not including NSAIDs or\n             corticosteroids used for IV dye allergy only)\n\n          -  Chronic inflammatory disease (including but not limited to rheumatoid arthritis,\n             systemic lupus erythematosus)\n\n          -  Known active malignancy of any type, or prior diagnosis in the past 10 years\n\n          -  Anticipated need for cardiac surgery\n\n          -  Active cancer (or prior diagnosis of cancer within the past 10 years)\n\n          -  Neutropenia (absolute neutrophil count<1,800/mm3)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950299", 
            "org_study_id": "VCU HM20000024"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Anakinra (standard dose)", 
                    "Anakinra (high dose)"
                ], 
                "description": "Anakinra 100 mg starting immediately and then every 24 hours", 
                "intervention_name": "Anakinra 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Anakinra (high dose)", 
                "description": "Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)", 
                "intervention_name": "Anakinra 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Anakinra (standard dose)", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo injections twice daily"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin 1 Receptor Antagonist Protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "contact": {
                "email": "aabbate@vcu.edu", 
                "last_name": "Antonio Abbate, MD, PhD", 
                "phone": "804-828-0513"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University"
            }, 
            "investigator": [
                {
                    "last_name": "Antonio Abbate, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Benjamin Van Tassell, PharmD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3", 
        "overall_contact": {
            "email": "aabbate@vcu.edu", 
            "last_name": "Antonio Abbate, MD, PhD", 
            "phone": "804-828-0513"
        }, 
        "overall_contact_backup": {
            "email": "bvantassell@vcu.edu", 
            "last_name": "Benjamin W Van Tassell, PharmD", 
            "phone": "804-828-4583"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: VCU-ART3 Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Placebo corrected difference in the area-under-the-curve for CRP up to day 14", 
            "measure": "Acute phase response (CRP levels)", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Placebo corrected interval change in left ventricular end-systolic volume indices over 12 months", 
                "measure": "Left ventricular end-systolic volume indices change", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Placebo-corrected interval changes in left ventricular ejection fraction over 12 months", 
                "measure": "Left ventricular ejection fraction", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "New onset of heart failure symptoms (NYHA II-IV)", 
                "measure": "Heart Failure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}